CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN

Abstract

The article describes international multicenter controlled studies of efficacy and safety of monoclonal antibodies towards interleukin 1β — kanakinumab — when treating cryopyrin-associated periodic syndrome and systemic juvenile idiopathic arthritis in children. The results of the studies show that the remission of the disease occurred in 90% of patients with cryopyrin-associated periodic syndrome and in 40% of patients with systemic juvenile idiopathic arthritis. The safety profile was comparable to that of other biological agents.

Keywords

• дети
• канакинумаб
• системный ювенильный идиопатический артрит
• криопиринассоциированные периодические синдромы